- Home
- CEF vs KRYS Comparison
CEF vs KRYS Comparison
Compare CEF & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEF
- KRYS
- Stock Information
- Founded
- CEF N/A
- KRYS 2015
- Country
- CEF
- KRYS United States
- Employees
- CEF N/A
- KRYS N/A
- Industry
- CEF
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CEF
- KRYS Health Care
- Exchange
- CEF NYSE
- KRYS Nasdaq
- Market Cap
- CEF 5.4B
- KRYS 4.6B
- IPO Year
- CEF N/A
- KRYS 2017
- Fundamental
- Price
- CEF $27.00
- KRYS $187.96
- Analyst Decision
- CEF
- KRYS Strong Buy
- Analyst Count
- CEF 0
- KRYS 7
- Target Price
- CEF N/A
- KRYS $210.00
- AVG Volume (30 Days)
- CEF N/A
- KRYS 245.3K
- Earning Date
- CEF N/A
- KRYS 02-19-2025
- Dividend Yield
- CEF N/A
- KRYS N/A
- EPS Growth
- CEF N/A
- KRYS 669.23
- EPS
- CEF N/A
- KRYS 3.00
- Revenue
- CEF N/A
- KRYS $290,515,000.00
- Revenue This Year
- CEF N/A
- KRYS $483.09
- Revenue Next Year
- CEF N/A
- KRYS $57.70
- P/E Ratio
- CEF N/A
- KRYS $62.62
- Revenue Growth
- CEF N/A
- KRYS 473.02
- 52 Week Low
- CEF N/A
- KRYS $109.57
- 52 Week High
- CEF N/A
- KRYS $219.34
- Technical
- Relative Strength Index (RSI)
- CEF 66.84
- KRYS 73.39
- Support Level
- CEF $26.46
- KRYS $148.00
- Resistance Level
- CEF $27.23
- KRYS $190.00
- Average True Range (ATR)
- CEF 0.26
- KRYS 7.31
- MACD
- CEF 0.02
- KRYS 3.66
- Stochastic Oscillator
- CEF 83.59
- KRYS 93.87
About CEF SPROTT PHYSICAL GOLD AND SILVER TR
Sprott Physical Gold and Silver Trust is a closed end mutual fund trust. The trust invests and holds all of its assets in physical gold and silver bullion and seeks to provide a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical bullion without the inconvenience that is typical of direct investment.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.